Positions

Overview

  • Dr. Kimo Bachiashvili is an assistant professor at the University of Alabama at Birmingham, in the Division of Hematology and Oncology. His clinical interests include Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Aplastic Anemia.

    Dr. Kimo Bachiashvili graduated from Tbilisi State Medical University in 2007. He then moved to the SUNY Upstate Medical University in Syracuse, New York as a Research Assistant in Dr. Timothy Damron’s laboratory. There he studied the role of hedgehog pathway inhibition in human alveolar rhabdomyosarcoma. He then started Medicine residency in Yale-New Haven Hospital in New Haven, Connecticut which he graduated in 2015. During residency, he focused on the CREB pathway as a target in AML while working in Dr. Stephanie Halene’s laboratory. During residency, he received Intern of the Year Elected by Peers award in 2013, Excellence in Ambulatory Care award in 2014, and Outstanding Efforts in Research award in 2015. After graduation in 2015, he joined Hematology and Oncology fellowship program in the Montefiore Medical Center / Albert Einstein College of Medicine in Bronx, New York under directorship of Dr. Rasim Gucalp. His research focus during fellowship was TGF-beta signaling in low-grade MDS which he conducted in Dr. Amit Verma’s laboratory. He also served as a Chief fellow in the last year of training: 2017-2018 academic year. In 2018, he received Outstanding Achievement in the Teaching of Medical Students award by Leo M. Davidoff Society of the Albert Einstein College of Medicine. In August 2018, Dr. Kimo Bachiashvili joined UAB, Division of Hematology and Oncology as a faculty.
  • Research Overview

  • 1. Characterization of the MDS abnormal clone
    2. Alteration of bone marrow microenvironment in MDS
    3. Acute Myeloid Leukemia therapy in the elderly
  • Investigator On

  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by ASTEX PHARMACEUTICALS
  • Private Grant  awarded by KARTOS THERAPEUTICS INC.
  • Private Grant  awarded by KARTOS THERAPEUTICS INC.
  • Private Grant  awarded by IMMUNOGEN, INC.
  • Private Grant  awarded by ONO PHARMACEUTICAL COMPANY LTD
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by TG THERAPEUTICS
  • Private Grant  awarded by IMMUNOGEN, INC.
  • Private Grant  awarded by CTI BIOPHARMA CORP
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by AVEO PHARMACEUTICALS, INC
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by TG THERAPEUTICS
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by FORTY SEVEN, INC.
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by TAKEDA DEVELOPMENT CENTER AMERICAS, INC.
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by SELLAS LIFE SCIENCES GROUP, INC.
  • Private Grant  awarded by BLUEPRINT MEDICINES CORPORATION
  • Private Grant  awarded by ASCENTAGE PHARMA GROUP INC
  • Private Grant  awarded by MARKER THERAPEUTICS INC
  • Private Grant  awarded by ASTEX PHARMACEUTICALS
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by KARTOS THERAPEUTICS INC.
  • Private Grant  awarded by CHIMERIX, INC.
  • Private Grant  awarded by DELTA-FLY PHARMA INC
  • Private Grant  awarded by KARTOS THERAPEUTICS INC.
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by MARKER THERAPEUTICS INC
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by CONSTELLATION PHARMACEUTICALS INC
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by Gilead Sciences ^
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University
  • UAB 19113: A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients with MDS and AML  awarded by SOUTHERN RESEARCH INSTITUTE
  • Education And Training

  • Doctor of Medicine, 2007
  • Full Name

  • Kimo Bachiashvili